Saturday 17 October 2026
Export CTOR’s income statement to Excel — free account
Citius Oncology, Inc.
CTOR Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS was flat, free cash flow was flat and total debt rose 79.3%, each against the same quarter a year earlier.
0.75
0.00
0.00%
Follow CTOR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (126.58%) | (119.90%) | (47.41%) | (54.42%) |
+8 more TTM periods Free account |
|
| (45.20%) | (44.25%) | (23.58%) | (26.72%) | ||
ROIC |
(67.15%) | (60.91%) | (21.06%) | (27.10%) | |
Return on Tangible Assets |
286.47% | 144.65% | 312.50% | 112.82% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(0.30) | (0.27) | (0.26) | (0.22) | |
Free Cash Flow |
(32.14) | (27.43) | (23.00) | (16.24) | |
Capital Expenditures |
(12.75) | (10.75) | (10.15) | (10.75) | |
| Other line items | |||||
Cash ROIC |
(41.66%) | (54.94%) | (28.39%) | (26.15%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.01 | 0.05 | 0.04 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(128.59) | (146.59) | (84.81) | (29.50) | |
Operating CF/Net income |
0.42 | 0.39 | 0.54 | 0.22 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
(3.04) | (4.69) | (17.70) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.18) | (0.17) | (0.15) | (0.07) | |
Capex per Share |
(0.12) | (0.11) | (0.12) | (0.15) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Oct 2026